Goldberg D, Lewis Jd, Halpern Sd, Weiner Mark, Lo Re Vincent
Department of Medicine, Division of Gastroenterology, University of Pennsylvania; Clinical Center for Biostatistics and Epidemiology, University of Pennsylvania.
Pharmacoepidemiol Drug Saf. 2012 Jul;21(7):765-769. doi: 10.1002/pds.3290. Epub 2012 Jun 4.
Use of administrative or population-based databases for post-marketing pharmacoepidemiology research in patients with end-stage liver disease (ESLD) has been limited by the difficulty of accurately identifying such patients. Algorithms to identify patients with ESLD using ICD-9-CM codes have not been developed outside of the Veterans Affairs healthcare setting. METHODS: We queried electronic medical records at two tertiary care hospitals to identify patients with ICD-9-CM codes indicative of ESLD. Coding algorithms were developed to identify patients with confirmed ESLD, and these were tested to determine their positive predictive value (PPV). RESULTS: The presence of one inpatient or outpatient ICD-9-CM code for: (i) cirrhosis; (ii) chronic liver disease, and (iii) a hepatic decompensation event yielded a PPV of 85.2% (167/196; 95% CI: 79.4%-89.9%). The PPV increased to 89.3% (150/168; 95% CI: 83.6%-93.5%) when the algorithm required two or more ICD-9-CM codes for a hepatic decompensation. However, an algorithm requiring only one ICD-9-CM code for (i) cirrhosis and (ii) a hepatic decompensation event, in the absence of a chronic liver disease code, yielded a PPV of 85.7% (30/35; 95% CI: 69.7%-95.2%). CONCLUSIONS: A coding algorithm that includes at least one ICD-9-CM code for cirrhosis plus one ICD-9-CM code for a hepatic decompensation event has a high PPV for identifying patients with ESLD. The inclusion of at least two codes indicative of a hepatic decompensation event increased the PPV. This algorithm can be used in future epidemiologic studies to examine the outcomes of a variety of long-term medical therapies in patients with ESLD. Copyright © 2012 John Wiley & Sons, Ltd.
在终末期肝病(ESLD)患者中,利用行政或基于人群的数据库进行上市后药物流行病学研究,一直受到准确识别此类患者困难的限制。除了退伍军人事务医疗保健机构外,尚未开发出使用国际疾病分类第九版临床修正版(ICD - 9 - CM)编码来识别ESLD患者的算法。方法:我们查询了两家三级护理医院的电子病历,以识别具有指示ESLD的ICD - 9 - CM编码的患者。开发了编码算法来识别确诊为ESLD的患者,并对其进行测试以确定其阳性预测值(PPV)。结果:存在以下一种住院或门诊ICD - 9 - CM编码:(i)肝硬化;(ii)慢性肝病;(iii)肝失代偿事件,其PPV为85.2%(167/196;95%置信区间:79.4% - 89.9%)。当算法要求肝失代偿有两个或更多ICD - 9 - CM编码时,PPV增加到89.3%(150/168;95%置信区间:83.6% - 93.5%)。然而,在没有慢性肝病编码的情况下,仅要求(i)肝硬化和(ii)肝失代偿事件有一个ICD - 9 - CM编码的算法,其PPV为85.7%(30/35;95%置信区间:69.7% - 95.2%)。结论:一种编码算法,包括至少一个用于肝硬化的ICD - 9 - CM编码加上一个用于肝失代偿事件的ICD - 9 - CM编码,在识别ESLD患者方面具有较高的PPV。纳入至少两个指示肝失代偿事件的编码可提高PPV。该算法可用于未来的流行病学研究,以检查ESLD患者各种长期药物治疗的结果。版权所有© 2012约翰威立父子有限公司。